Treatment, the outcome of COVID-19-associated pneumothorax and outcome of patients with COVID-19 without pneumothorax
| Outcome/treatment | COVID-19-associated pneumothorax | COVID-19 not associated with pneumothorax |
| Side of pneumothorax N (%) | NA | |
| Bilateral | 12 (16) | |
| Left | 21 (28) | |
| Right | 42 (56) | |
| Chest tube insertion n (%) | 59 (78.7) | NA |
| Duration of a chest tube (median IQR) | 8 (4–18) | NA |
| Recurrences n (%) | 7 (9.3) | NA |
| Length of ICU stay (days) | ||
| (Median +IQR) | 28 (20.5–45.8) days | 14(±20.5) days |
| (Mean±SD) | 39.2 (±32.9) days | |
| Length of NIV after developing pneumothorax (days) (median IQR) | 4 (3.5–15) days | NA |
| Length of IV after developing pneumothorax (median IQR) | 13 (6–32) days | NA |
| Need for tracheostomy n (%) | 33 (44%) | NA |
| No of days in ICU before developing pneumothorax (median IQR) | 15 (6–23) days | NA |
| Time elapsed from first COVID-19 PCR to development of pneumothorax (days) (median IQR) | 21 (13.5–32) days | NA |
| Time to negative COVID-19 PCR (days) (median IQR) | 28 (24–42) days (maximum 138) | NA |
| In-hospital mortality n (%) | 40 (53.3) | 236 (13.1) |
ICU, intensive care unit; IV, invasive ventilation; NA, not available; NIV, non-invasive ventilation.